Results 31 to 40 of about 6,506,258 (188)
Interferon gamma inducible protein 16 (IFI16) expression is reduced in mantle cell lymphoma
IFI16, member of the IFN-inducible PYHIN-200 gene family, modulates proliferation, survival and differentiation of different cell lineages. In particular, IFI16 expression, which is regulated during the differentiation of B cells, was recently studied in
Pier Paolo Piccaluga +13 more
doaj +1 more source
Non-Nodal CD5-Negative Mantle Cell Lymphoma with Secondary TP53 Deletion
Mantle cell lymphoma is a non-Hodgkin lymphoproliferative neoplasm with several clinical and morphologic variants linked, primarily, through genetic derangement of the cyclin D1 locus.
Robert K. McCall +2 more
doaj +1 more source
The potential therapeutic role of selenium in diffuse large B-cell lymphoma [PDF]
PhDThe clinical background to this work confirms the very poor outcome of patients with recurrent diffuse large B-cell lymphoma (DLBCL) and highlights the need for better therapies.
Kassam, Shireen
core +3 more sources
RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma. [PDF]
Mantle cell lymphoma is characterized by a genetic translocation results in aberrant overexpression of the CCND1 gene, which encodes cyclin D1. This protein functions as a regulator of the cell cycle progression, hence is considered to play an important ...
Shiri Weinstein +8 more
doaj +1 more source
Background Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin's lymphoma that originates from small to medium sized lymphocytes located in the mantle zone of the lymph node. Extra nodal involvement is present in the majority of cases,
Abo Stephen M +6 more
doaj +1 more source
Mantle cell lymphoma (MCL) accounts for approximately 6% of all non-Hodgkin’s lymphomas[1][1] and is characterized by the over-expression of cyclin D1 with cell cycle dysregulation, secondary to the genetic abnormality t(11;14)(q13;q32).[2][2] It often has an aggressive clinical course and ...
Michelle Furtado, Simon Rule
openaire +3 more sources
Mantle cell lymphoma of the colon [PDF]
An 81-year-old man with a history of stage IV mantle cell lymphoma (MCL) diagnosed from a submental lymph node biopsy in 2006 was evaluated for new-onset melena and blood clots with bowel movements. He had been treated for his MCL with 6 cycles of CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab) in 2006, followed by 13 ...
Mohammad, Esmadi +3 more
openaire +2 more sources
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma [PDF]
We report the outcomes after reduced-intensity conditioning allogeneic stem cell transplantation (RIT) for non-Hodgkin lymphoma (NHL) in 88 patients (low-grade NHL [LG-NHL], n = 41; high-grade NHL [HG-NHL], n = 37; mantle cell lymphoma [MCL], n = 10 ...
Mahendra, P +37 more
core +1 more source
Mantle cell lymphoma presented as enteric intussusception and involved gallbladder
Intussusception caused by a lymphomatous mass is extremely rare in adults. To date, only four cases of mantle cell lymphoma have intussusception as a treatment sequelae or complication.
Chih-Ching Chin +2 more
doaj +1 more source
Mitochondrial localization of Cx26 emerges as a double‐edged sword in colorectal cancer. PIMT‐mediated methylation of Cx26 promotes its mitochondrial localization and stability. Mitochondrial Cx26 then facilitates ER‐mitochondria communication and Ca2+ signaling, thereby promoting metastatic progression. Bortezomib exploits this malignant adaptation by
Jie Wang +9 more
wiley +1 more source

